Loading clinical trials...
Loading clinical trials...
Phase 1/2, Randomized, Observer-Blind, Parallel, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults ≥18 Years of Age
Conditions
Interventions
mRNA-1018 for H5N8
mRNA-1018 for H7N9
+3 more
Locations
27
United States
CenExel RCA
Hollywood, Florida, United States
Velocity Clinical Research
Savannah, Georgia, United States
Johnson County Clin-Trials
Lenexa, Kansas, United States
DM Clinical Research
Southfield, Michigan, United States
Velocity Clinical Research
Lincoln, Nebraska, United States
Velocity Clinical Research Providence
East Greenwich, Rhode Island, United States
Start Date
July 10, 2023
Primary Completion Date
July 16, 2024
Completion Date
July 16, 2024
Last Updated
July 16, 2025
NCT07291635
NCT06094010
NCT06417762
NCT06160128
NCT07396428
NCT07310472
Lead Sponsor
ModernaTX, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions